We have shown that sub-prophylactic doses of unfractionated heparin (UFH) can inhibit spike protein interactions with host cells whereas low molecular weight heparins (LMWH) such as enoxaparin and dalteparin are less effective. These findings have implications for the treatment of COVID-19. Current treatment often involves the administration of LMWH in the later stages when widespread blood clotting occurs. Earlier administration of UFH, or the delivery of nebulised heparin directly to the worst-affected organ, the lungs, may be an interesting therapeutic intervention to explore.
Dr Peter Monk, Professor of Immunology, University of Sheffield Medical School
We provide a collection of high quality Heparan Sulfate (HS) antibodies. These HS antibodies include F69-3G10, F58-10E4 and JM403 clones, which have been proven useful for targeted detection of varying levels of sulfated HS specific thought to be important in virus attachment.
Heparan Sulfate is synthesized as the glycosaminoglycan (GAG) component of Heparan Sulfate Proteoglycans. It is expressed on the cell surface of virtually all cell types and basement membranes in mammals. It displays specific interactions with many biologically active proteins and, thus, is involved in many important biological processes. The non-immunogenic character of HS makes raising antibodies to this target very difficult, so the few hybridoma-derived mouse anti-HS antibodies such as JM403, 10E4 and 3G10 are valuable tools for HS research.
For further information on the research group led by Professor Peter Monk, visit https://www.sheffield.ac.uk/medicine/people/iicd/peter-monk.
Be the first to hear about upcoming events, product news, special offers, application notes, and more